Same-visit Hepatitis C Testing and Treatment (The QuickStart Study)

• Status: Not yet recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The QuickStart study aims to assess the impact of three models of HCV care on HCV treatment uptake and cure among people who inject drugs. Rapid point-of-care (POC) HCV testing and test-and-treat strategies will be utilised in primary health care settings across Australia.

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Macfarlane Burnet Institute for Medical Research and Public Health Ltd
• Treatments: Antibodies; Hepatitis C Antibodies; Sofosbuvir; Velpatasvir

Criteria

Inclusion Criteria:

• current or former PWID (i.e., injected drugs at least once)

• aged 18 years or over

• attending a participating PHC for any reason

• no previous treatment with DAAs for HCV

• failed interferon based treatment for HCV in the past (i.e., did not achieve cure)

• Medicare eligible

• able to speak and understand English

Exclusion Criteria:

• women known to be currently pregnant or who are breastfeeding

• individuals self-reporting to be currently engaged in treatment for HCV

• unable to provide informed consent

• tested for HCV in the past 3 months